Blog

by Heidi Hagen and Christophe Suchet | February 21, 2020
This post is the eighth in an eight-part series on data management strategies for personalized therapeutics, such as cell therapies, gene therapies, or neoantigen cancer vaccines.

by Heidi Hagen and Christophe Suchet | February 19, 2020
This post is the seventh in an eight-part series on data management strategies for personalized therapeutics, such as cell therapies, gene therapies, or neoantigen cancer vaccines.

by Heidi Hagen and Christophe Suchet | February 12, 2020
This post is the sixth in an eight-part series on data management strategies for personalized therapeutics, such as cell therapies, gene therapies, or neoantigen cancer vaccines.

by Heidi Hagen and Christophe Suchet | February 11, 2020
This post is the fifth in an eight-part series on data management strategies for personalized therapeutics, such as cell therapies, gene therapies, or neoantigen cancer vaccines.

by Amy DuRoss and Heidi Hagen | February 5, 2020
On February 5th, 2020, we announced Vineti’s $35 million Series C round of investment. A first-of-its-kind investor coalition of industry leaders -- Cardinal Health, Novartis Pharma AG, and Kite, a Gilead Company -- came together with our current…

Subscribe to our blog
Required
Required
Required
Required
Required
Required
Required